



Dear Healthcare Professional:

Opioid use disorder (addiction) and overdose from opioid analgesics and heroin constitute a significant public health problem in New York City. Overdose deaths from opioids are increasing even though they are preventable. In 2015, there were 937 unintentional drug overdose deaths in New York City, nearly all (97%) overdose deaths involved more than one substance use. Eight in ten (80%) overdose deaths involved an opioid. Opioid analgesics, excluding fentanyl were involved in 214 (23%) of overdose deaths. The rates of overdose deaths involving opioid analgesics were highest among residents of Staten Island.

Although opioid use disorder has serious consequences, many New Yorkers with this chronic health condition do not receive effective treatment. Medication assisted treatment with medications such as buprenorphine, methadone, and vivitrol is a life - saving tool with benefits to the patients and the community. Buprenorphine is an office based treatment that can be integrated into primary care along with management of patients' other health issues. Despite buprenorphine's many benefits, it remains underutilized.

As a waived provider you can make treatment for opioid use disorder more available to those who need it and be part of the public health effort to reverse the epidemic of opioid use disorder and overdose. Medication assisted treatment such as buprenorphine is effective and achieves better long term health and social outcomes. Providing this treatment can help reduce mortality and drug use, and promote a return to social functioning such as improved quality of life, employment, and personal relationships.

Access to buprenorphine in primary care settings, however, remains uneven leaving many individuals with opioid use disorders without the treatment they need. Several barriers hinder expansion of buprenorphine access in practice settings including: lack of physician time to manage and coordinate care for patients with opioid use disorders; lack of familiarity with using buprenorphine and managing addiction; and lack of access to behavioral health counseling for patients.

In order to address these barriers, The Staten Island Partnership for Community Wellness (SIPCW) and the Staten Island Performing Providers System (SI PPS) are working to help waived providers overcome the barriers that hinder them from using their waiver to its capacity.

We will be reaching out to you to schedule a visit to assess your practice needs and to develop a plan to help you meet your goals. We will also be offering to link you to resources at the local and city level. In the interim, please contact Nadeen Makhoulf at 718-215-8303 with any questions or concerns.

Sincerely,

Nadeen Makhoulf Pharm D., MPH
Sr. Coordinator Clinical Outreach & Education
Staten Island Partnership for Community Wellness (SIPCW)



City Health Information

Volume 34 (2015)

The New York City Department of Health and Mental Hygiene

No. 1; 1-8

BUPRENORPHINE—AN OFFICE-BASED TREATMENT FOR OPIOID USE DISORDER

- Buprenorphine treatment is a life-saving tool for patients with opioid use disorder.
- Learn to recognize opioid use disorder and recommend effective treatment.
- Incorporate buprenorphine treatment into your practice.

Opioid use disorder (addiction) and overdose from opioid analgesics and heroin constitute a significant public health problem in New York City (NYC). Overdose deaths from opioids are increasing—even though they’re preventable. Between 2000 and 2013, opioid analgesic overdose deaths increased 256%.¹ Heroin overdose deaths doubled between 2010 and 2013 after declining for several years.¹

Of the 782 NYC overdose deaths in 2013, 215 involved opioid analgesics and 420 involved heroin.¹

Although opioid use disorder has serious consequences, many New Yorkers with this chronic health condition do not receive effective treatment. Medication-assisted treatment (eg, buprenorphine and methadone) for opioid use disorder is a life-saving tool—with benefits to patients and the community²⁻⁵ (**Boxes 1 and 2, Figure**). Buprenorphine is an office-based treatment that can be integrated into primary care along with management of patients’ other health issues.⁶ Despite buprenorphine’s many benefits, it remains underutilized. By following the guidance in this publication, you can make treatment for opioid use disorder more available to those who need it and be part of the public health effort to reverse the epidemic of opioid use disorder and overdose.

To incorporate buprenorphine treatment into your practice, follow these steps:

1. Learn to recognize opioid use disorder.
2. Obtain training and a waiver to prescribe buprenorphine.
3. Prescribe buprenorphine to patients with opioid use disorder.
4. Provide ongoing management of patients with opioid use disorder.

Continuing education training and mentorship from experienced clinicians are also available online (**Resources**).

WHAT ARE OPIOIDS?

- *Opioids* are drugs that bind to specific receptors in the brain and relieve pain. The group includes both heroin and opioid analgesics.
- *Opioid analgesics* are medications legally prescribed as painkillers, such as morphine, oxycodone, and hydrocodone.



BOX 1. BUPRENORPHINE FAQs

• How does buprenorphine work?

Buprenorphine is a partial opioid agonist, attaching to the same receptors in the brain as other opioids (eg, opioid analgesics, heroin, methadone), but producing only weak morphine-like effects, without the euphoria or respiratory depression triggered by full opioid agonists. These effects increase with dosage, but plateau at a moderate dosage. As a partial opioid agonist, buprenorphine at a moderate dosage enables patients to discontinue use of other opioids without experiencing withdrawal symptoms.⁷

• How is buprenorphine taken?

Buprenorphine is available in tablet or film and is generally administered once daily under the tongue. The tablets completely dissolve within 5 to 10 minutes, and the film dissolves even more rapidly. Buprenorphine is available in 2 formulations:


- *Buprenorphine and naloxone (because naloxone precipitates withdrawal symptoms when injected, but not when taken orally, it is included in the formulation as a deterrent to intravenous use of buprenorphine)⁷*
- *Buprenorphine only*

The buprenorphine/naloxone combination is preferable in all cases, except when the patient is hypersensitive to naloxone or pregnant (see Review safety considerations, page 4).

• What about overdose?

*Buprenorphine's weak morphine-like effects increase with dosage, but plateau at a moderate dosage (the "ceiling effect"), making it difficult for a person to overdose on buprenorphine alone. **Fatal overdose is still possible if other central nervous system depressants, such as benzodiazepines or alcohol, are taken along with buprenorphine.⁷***

FIGURE. BUPRENORPHINE MECHANISM OF ACTION



STEP 1. LEARN TO RECOGNIZE OPIOID USE DISORDER

- Ask nonjudgmental, open-ended questions about a patient's functioning with his or her family, at work or school, and in social situations.
- Be aware of signs associated with opioid intoxication such as drowsiness, slurred speech, memory impairment, and pupillary constriction.⁷
- Screen for drug use. Ask "How many times in the past year have you used an illegal drug or used a prescription medication for nonmedical reasons?"⁸ If the response is ≥ 1 , use one of several validated screening tools available, such as the DAST-10 (**Box 3**). See **Resources—Clinical Tools** for other options.
- For patients who respond "Yes" to ≥ 3 questions on the DAST-10, use criteria in the *Diagnostic and Statistical Manual of Mental Disorders (DSM-5)* (**Box 4**) to assess for mild, moderate, or severe opioid use disorder (this term replaces the previous DSM terms "opioid abuse" and "opioid dependence").⁹

BOX 2. BUPRENORPHINE MISUSE: MYTHS AND FACTS

MYTH: Buprenorphine is just as likely to be misused as other opioids.

FACT: Risk of misuse is lower with buprenorphine than with full opioid agonists.¹⁰ Buprenorphine is long-acting and exhibits a ceiling effect, limiting euphoria. The naloxone in the coformulated buprenorphine works to deter injection: it's an opioid antagonist that produces withdrawal symptoms if injected, but not when it's absorbed sublingually, as indicated.⁷

MYTH: People who've used buprenorphine without a prescription are not candidates for buprenorphine treatment.

FACT: The most common reasons for buprenorphine misuse are self-treatment of withdrawal symptoms and lack of access to treatment.^{11,12} Most patients who've misused buprenorphine in the past will still be appropriate treatment candidates, but it's important to evaluate the circumstances before prescribing buprenorphine.

⁹Using someone else's buprenorphine or using buprenorphine in ways other than prescribed.

BOX 3. DRUG USE QUESTIONNAIRE (DAST-10)

The following questions concern information about your potential involvement with drugs, excluding alcohol and tobacco, during the past 12 months. Carefully read each statement and decide if your answer is "YES" or "NO."

When the words "drug abuse" are used, they mean the use of prescribed or over-the-counter medications used in excess of the directions and any non-medical use of any drugs. The various classes of drugs may include, but are not limited to, cannabis (eg, marijuana, hash), solvents (eg, gas, paints, etc), tranquilizers (eg, Valium), barbiturates, cocaine, and stimulants (eg, speed), hallucinogens (eg, LSD), or narcotics (eg, heroin). Remember that the questions do not include alcohol or tobacco.

Please answer every question. If you have difficulty with a statement, then choose the response that is mostly right.

These questions refer to the past 12 months only.

| | | |
|--|-----|----|
| 1. Have you used drugs other than those required for medical reasons? | Yes | No |
| 2. Do you abuse more than one drug at a time? | Yes | No |
| 3. Are you always able to stop using drugs when you want to? | Yes | No |
| 4. Have you had "blackouts" or "flashbacks" as a result of drug use? | Yes | No |
| 5. Do you ever feel bad or guilty about your drug use? | Yes | No |
| 6. Does your spouse (or parent) ever complain about your involvement with drugs? | Yes | No |
| 7. Have you neglected your family because of your use of drugs? | Yes | No |
| 8. Have you engaged in illegal activities in order to obtain drugs? | Yes | No |
| 9. Have you ever experienced withdrawal symptoms (felt sick) when you stopped taking drugs? | Yes | No |
| 10. Have you had medical problems as a result of your drug use (eg, memory loss, hepatitis, convulsions, bleeding, etc)? | Yes | No |



BOX 4. DSM-5 CRITERIA FOR OPIOID USE DISORDER⁹

Ask opioid users if they have experienced these symptoms in the past year:

- Taking the substance in larger amounts or for longer than you meant to,
- Wanting to cut down or stop using the substance but not managing to,
- Spending a lot of time getting, using, or recovering from use of the substance,
- Cravings and urges to use the substance,
- Not managing to do what you should at work, home, or school because of substance use,
- Continuing to use, even when it causes problems in relationships,
- Giving up important social, occupational, or recreational activities because of substance use,
- Using substances again and again, even when it puts you in danger,
- Continuing to use, even when you know you have a physical or psychological problem that could have been caused or made worse by the substance,
- Needing more of the substance to get the effect you want (tolerance),*
- Development of withdrawal symptoms, which can be relieved by taking more of the substance.*

2-3 symptoms: mild opioid use disorder

4-5 symptoms: moderate opioid use disorder

6+ symptoms: severe opioid use disorder

* Persons who are prescribed medications such as opioids may exhibit these two criteria, but would not necessarily be considered to have opioid use disorder.

STEP 2. OBTAIN TRAINING AND A WAIVER TO PRESCRIBE BUPRENORPHINE

To prescribe buprenorphine, you must meet the following 3 criteria¹³:

- Be a licensed physician (MD or DO).
- Have any of the following credentials:
 - completion of at least 8 hours of a specific continuing medical education (CME) training (online or in person) from an approved organization on prescribing buprenorphine (**Resources**),
 - subspecialty board certification related to addiction, or
 - investigator role in 1 or more clinical trials leading to Food and Drug Administration approval of a narcotic for drug maintenance or detoxification.
- Have the capacity to refer patients to counseling. In NYC, you can meet this criterion by referring patients to 800-LIFENET, or 311.

If you meet all 3 criteria, you can obtain a waiver to prescribe buprenorphine from the Drug Enforcement Administration. Once you're qualified, you may have a maximum of 30 patients on buprenorphine at any one time during the first year. After 1 year following the initial notification, you can submit a second notification to enable you to treat up to 100 patients. Call the Center for Substance Abuse Treatment (CSAT) at 866-BUP-CSAT/866-287-2728 or visit <http://buprenorphine.samhsa.gov/training.html> for information about the waiver process.

*If you are not able to
prescribe buprenorphine, go to
[http://buprenorphine.samhsa.gov/
bwns_locator/index.html](http://buprenorphine.samhsa.gov/bwns_locator/index.html)
or call 866-BUP-CSAT/866-287-2728
or LIFENET (800-LIFENET) to
find a buprenorphine prescriber.*

STEP 3. PRESCRIBE BUPRENORPHINE TO PATIENTS WITH OPIOID USE DISORDER

The treatment goals for opioid use disorder are to block the euphoric effects of opioids, alleviate physical withdrawal symptoms and reduce psychological cravings, and help patients regain or acquire the ability to function in their personal, community, and work lives.

Talk with your patient

- Buprenorphine may be a good choice for patients who⁷
- meet the DSM-5 criteria for opioid use disorder,
 - can be expected to be reasonably adherent to the treatment plan, based on provider's experience,

- have been educated about the risks and benefits of buprenorphine treatment,
- are willing to follow safety precautions for buprenorphine treatment,
- have agreed to buprenorphine treatment after a review of treatment options.

Draft a treatment agreement

- A written agreement (**Resources**) will help establish mutual trust and clarify expectations of patient involvement in buprenorphine treatment.⁷

Review safety considerations^a

- **Sedatives/hypnotics** (eg, benzodiazepines, alcohol): If a benzodiazepine or other central nervous system (CNS) depressant is medically necessary, monitor the patient for side effects—particularly sedation and respiratory depression. **The combination of buprenorphine and other CNS depressants can be fatal.**⁷
- **Hepatic impairment:** Evidence demonstrates a low risk of hepatotoxicity; consider monitoring liver function during treatment.¹⁴
- **HIV:** Buprenorphine is associated with reduced opioid use, increased initiation of antiretroviral therapy, and increased CD4 counts,¹⁵ and has been effectively and safely integrated into HIV treatment settings.¹⁶ Clinical data haven't shown hepatotoxicity or pharmacodynamic interactions when buprenorphine is used with antiretroviral therapy, including atazanavir/ritonavir,¹⁴ which increases plasma concentrations of buprenorphine and its metabolite norbuprenorphine.¹⁷
- **Pregnancy:** Methadone remains the standard of care in the United States, but buprenorphine (without naloxone) may be used as first-line treatment for pregnant women who've been maintained successfully on buprenorphine or are unwilling to take methadone.¹⁸
- **Lactation:** Breastfeeding is not contraindicated.⁷ While small amounts of buprenorphine and norbuprenorphine are secreted into breast milk, adverse events have not been reported among breastfed infants of mothers treated with sublingual buprenorphine.^{19,20}
- **Adverse events:** The most common adverse events are rashes, hives, and pruritus. Bronchospasm, angioneurotic edema, and anaphylactic shock have also been reported. Buprenorphine products should not be given to those who are hypersensitive to buprenorphine or naloxone.⁷
- **Illicit substances:** There is no medical rationale for discontinuing buprenorphine for most patients who continue to use other drugs:
 - There have been no documented adverse interactions between buprenorphine and cocaine or marijuana, but patients who use cocaine may need additional interventions.²¹⁻²⁴

- Some patients who use multiple substances might need a higher level of care, such as a specialized addiction treatment program; others may benefit from continued management with buprenorphine in the general medical setting.

See product information for full safety information.

Assess severity of withdrawal

Typically, patients must show at least mild withdrawal symptoms before beginning buprenorphine or they risk developing a precipitated or severe withdrawal.^{7,25} A score of ≥ 5 on the standardized Clinical Opiate Withdrawal Scale (COWS) (**Resources**) is the recommended threshold²⁵; higher scores reduce the chances of precipitating withdrawal.

Determine location of treatment initiation

Several studies have established the safety of home inductions. Office-based prescribers will likely find home inductions more feasible and can consult published guidance.²⁶⁻²⁸

Determine optimal dosage

The average daily buprenorphine dosage is 16 mg/day.²⁹ Few patients require—and many health plans will not pay for—dosages higher than 24 mg/day. Underdosing can result in craving and withdrawal symptoms, which could cause patients to drop out of treatment, and dosages that are too high can cause sedation.⁷

- Initiate treatment according to the package insert.
- Monitor patients for approximately 2 weeks after initiating therapy until you've determined the adequate buprenorphine dosage.
 - Substances that inhibit the 3A4 enzyme (eg, macrolide antibiotics, protease inhibitors) can increase plasma levels of buprenorphine. Substances that induce the 3A4 system (eg, phenobarbital) may have the opposite effect.⁷

For patients who are switching from methadone,

- Coordinate to taper the patient to 30 to 60 mg of methadone before starting buprenorphine.



Photos of brand name-products are for informational purposes only and do not imply endorsement by the New York City Department of Health and Mental Hygiene.

STEP 4. PROVIDE ONGOING MANAGEMENT OF PATIENTS WITH OPIOID USE DISORDER

- Tailor frequency of return visits to the patient and degree of clinical stability. Weekly or more frequent visits may be needed for a patient early in treatment or during unstable periods. Longer visit intervals, such as monthly, may be appropriate for the stable patient. Incorporate the following into follow-up visits:
 - relapse prevention counseling,⁷
 - assessment of adherence to prescribed buprenorphine,
 - urine toxicology as an adjunct to assess drug use and, if appropriate, buprenorphine adherence,⁷
 - assessment for mood, anxiety, or personality disorders.⁷
- Offer referral to counseling or a 12-step program. These services can help the patient manage psychological or psychosocial problems that could interfere with treatment gains.⁷
- Provide a clear protocol for refilling prescriptions to ensure continuous treatment.
- Remain attentive to frequent requests for early refills or reports of lost medication. These could be signs of misuse, which might indicate self-treatment of withdrawal and a need to increase prescribed dosage. Requests for more medication could also signal diversion to individuals who do not have access to a buprenorphine prescription or who are self-treating opioid withdrawal.^{11,12}
- If the patient continues to misuse opioids during maintenance treatment,
 - discuss treatment goals in a nonjudgmental manner, emphasizing a collaborative relationship, and minimize confrontation.
 - intensify treatment by reducing follow-up intervals, reassessing the medication dosage, and referring for more intensive psychosocial counseling or specialized addiction treatment.

INTEGRATE BUPRENORPHINE TREATMENT INTO PRACTICE WORKFLOW

- Assign a staff member such as a nurse or clinical pharmacist to coordinate the buprenorphine program, keep an electronic registry of buprenorphine patients, and manage refill requests.
- Plan for referral or on-site psychosocial counseling; in settings where a behavioral specialist and primary care physician provide collaborative care, group visits may be a feasible approach.
- Ensure coverage by a waived physician during vacations to minimize disruptions in treatment.

Reducing dosage and discontinuing treatment

Make the decision to discontinue buprenorphine treatment in partnership with the patient after assessing quality of life and social functioning. People who've been opioid dependent for short periods may be able to discontinue buprenorphine therapy; those who've been using opioids over long periods with a history of relapse will likely need long-term treatment.³⁰ Abrupt discontinuation or rapid dosage taper may result in opioid withdrawal syndrome, so work closely with the patient on a tapering schedule to avoid relapse. Refer to the package insert for full prescribing information, including dosing and safety. Be prepared to reinstate treatment if necessary.⁷

SUMMARY

Buprenorphine is a life-saving office-based treatment for opioid use disorder. Integrating buprenorphine prescribing into your practice will make treatment for opioid use disorder more available to those who need it and reduce stigmatization that may deter people from seeking care. ♦

Buprenorphine Treatment Finder:
866-BUP-CSAT/866-287-2728
http://buprenorphine.samhsa.gov/bwns_locator/index.html



RESOURCES

Clinical Tools

- DAST-10:
<http://smchealth.org/sites/default/files/docs/1309587937DRUGUSEQUESTIONNAIRE.pdf>
- ASSIST: www.who.int/substance_abuse/activities/assist/en/
- NIDA Quick Screen and NIDA-Modified ASSIST:
www.drugabuse.gov/publications/resource-guide-screening-drug-use-in-general-medical-settings/nida-quick-screen
- Clinical Opiate Withdrawal Scale (COWS):
www.naabt.org/documents/COWS_induction_flow_sheet.pdf

General Information About Buprenorphine:

<http://buprenorphine.samhsa.gov/index.html>

Buprenorphine Training Courses

- Substance Abuse and Mental Health Service Administration (SAMHSA): 866-BUP-CSAT/866-287-2728;
<http://buprenorphine.samhsa.gov/training.html>
- American Academy of Addiction Psychiatry:
www.aaap.org
- American Osteopathic Academy of Addiction Medicine:
www.aoaam.org
- American Psychiatric Association: www.psychiatry.org
- American Society of Addiction Medicine: www.asam.org

Buprenorphine Waiver Process and Forms:

<http://buprenorphine.samhsa.gov/howto.html>

Physician-Patient Sample Treatment Agreement:

www.ncbi.nlm.nih.gov/books/NBK64238/

PCSS-MAT Mentoring Program for Prescribers:

<http://pcssmat.org/mentoring/>

LIFENET (a free, confidential help line for New York City residents; 24 hours a day/7 days a week):

In English: 800-LIFENET/800-543-3638

In Spanish: 877-AYUDESE/877-298-3373

In Korean and Chinese (Mandarin and Cantonese dialects):
877-990-8585

For other languages, call 800-LIFENET and ask for an interpreter.
TTY hard of hearing, call 212-982-5284

www.nyc.gov/html/doh/html/mental/lifenet.shtml

REFERENCES

- Paone D, Tuazon E, Bradley O'Brien D, Nolan M. Unintentional drug poisoning (overdose) deaths involving opioids in New York City, 2000-2013. *Epi Data Brief*. 2014;(50):1-4. www.nyc.gov/html/doh/downloads/pdf/epi/databrief50.pdf. Accessed February 13, 2015.
- Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. *BMJ*. 2010;341:c5475.
- Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O'Connor PG. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. *JAMA Intern Med*. 2014;174(12):1947-1954.
- Alford DP, LaBelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. *Arch Intern Med*. 2011;171(5):425-431.
- Fiellin DA, Moore BA, Sullivan LE, et al. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. *Am J Addict*. 2008;17(2):116-120.
- Arfken CL, Johanson CE, di Menza S, Schuster CR. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians. *J Subst Abuse Treat*. 2010;39(2):96-104.
- Center for Substance Abuse Treatment, *Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction*. A Treatment Improvement Protocol TIP 40. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004. www.ncbi.nlm.nih.gov/books/NBK64245/pdf/TOC.pdf. Accessed November 12, 2014.
- Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening test for drug use in primary care. *Arch Intern Med*. 2010;170(13):1155-1160.
- American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition*. Arlington, VA: American Psychiatric Association; 2013.
- Cicero TJ, Surratt HL, Inciardi J. Use and misuse of buprenorphine in the management of opioid addiction. *J Opioid Manag*. 2007;3(6):302-308.
- Genberg BL, Gillespie M, Schuster CR, et al. Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland. *Addict Behav*. 2013;38(12):2868-2873.
- Lofwall MR, Havens JR. Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine. *Drug Alcohol Depend*. 2012;126(3):379-383.
- Substance Abuse and Mental Health Services Administration. Buprenorphine. Physician waiver qualifications. The Drug Addiction Treatment Act of 2000 (DATA 2000). http://buprenorphine.samhsa.gov/waiver_qualifications.html. Accessed November 2, 2014.
- Vergara-Rodriguez P, Tozzi MJ, Botsko M, et al; BHIVES Collaborative. Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients. *J Acquir Immune Defic Syndr*. 2011;56(suppl 1):S62-S67.
- Altice FL, Bruce RD, Lucas GM, et al; BHIVES Collaborative. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. *J Acquir Immune Defic Syndr*. 2011;56(suppl 1):S22-S32.
- Fiellin DA, Weiss L, Botsko M, et al; BHIVES Collaborative. Drug treatment outcomes among HIV-infected opioid dependent patients receiving buprenorphine/naloxone. *J Acquir Immune Defic Syndr*. 2011;56(suppl 1):S33-S38.
- McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. *Am J Addict*. 2010;19(1):4-16.
- ACOG Committee on Health Care for Underserved Women; American Society of Addiction Medicine. ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy. *Obstet Gynecol*. 2012;119(5):1070-1076.
- Academy of Breastfeeding Medicine Protocol Committee; Jansson LM. ABM clinical protocol #21: Guidelines for breastfeeding and the drug-dependent woman. *Breastfeed Med*. 2009;4(4):225-228.
- Mozurkewich EL, Rayburn WF. Buprenorphine and methadone for opioid addiction during pregnancy. *Obstet Gynecol Clin N Am*. 2014;41(2):241-253.
- Cunningham CO, Giovanniello A, Kunins HV, Roose RJ, Fox AD, Sohler NL. Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users. *Am J Addict*. 2013;22(4):352-357.
- Sullivan LE, Moore BA, O'Connor PG, et al. The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence. *Am J Addict*. 2010;19(1):53-58.
- Budney AJ, Bickel WK, Amass L. Marijuana use and treatment outcome among opioid-dependent patients. *Addiction*. 1998;93(4):493-503.
- Epstein DH, Preston KL. Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? A review of past findings, and more evidence against. *Addiction*. 2003;98(3):269-279.
- Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). *J Psychoactive Drugs*. 2003;35(2):253-259.
- Cunningham CO, Giovanniello A, Li X, Kunins HV, Roose RJ, Sohler NL. A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions. *J Subst Abuse Treat*. 2011;40(4):349-356.
- Lee JD, Grossman E, DiRocco D, Gourevitch MN. Home buprenorphine/naloxone induction in primary care. *J Gen Intern Med*. 2009;24(2):226-232.
- Gunderson EW, Wang XQ, Fiellin DA, Bryan B, Levin FR. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial. *Addict Behav*. 2010;35(5):537-540.
- Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database Syst Rev*. 2014;2:CD002207.
- Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. *Arch Gen Psychiatry*. 2011;68(12):1238-1246.



42-09 28th Street, Long Island City, NY 11101 (347) 396-2914

Bill de Blasio

Mayor

Mary T. Bassett, MD, MPH

Commissioner of Health and Mental Hygiene

Division of Mental Hygiene

Gary Belkin, MD, PhD, MPH, Executive Deputy Commissioner

Myla Harrison, MD, MPH, Medical Director

Bureau of Alcohol and Drug Use Prevention, Care and Treatment

Hillary V. Kunins, MD, MPH, MS, Assistant Commissioner

Jessica Kattan, MD, MPH, Director, Primary Care Integration Unit

Denise Paone, EdD, Director, Research and Surveillance Unit

Consultants

Aaron D. Fox, MD, MS, Assistant Professor of Medicine, Division of General Internal Medicine,
Albert Einstein College of Medicine/Montefiore Medical Center

Chinazo O. Cunningham, MD, MS, Professor of Medicine, Associate Chief, Division of General
Internal Medicine, Albert Einstein College of Medicine/Montefiore Medical Center

Division of Epidemiology

Charon Gwynn, PhD, Deputy Commissioner

Provider Education Program

Ram Koppaka, MD, PhD, Director

Peggy Millstone, Director, Scientific Education Unit

Peter Ephross, Medical Editor

Rhoda Schlamm, Medical Editor

Copyright ©2015 The New York City Department of Health and Mental Hygiene

E-mail *City Health Information* at: nycdohrp@health.nyc.gov

Suggested citation: Kattan J, Fox AD, Cunningham CO, Paone D, Harrison M, Kunins HV.

Buprenorphine—an office-based treatment for opioid use disorder. *City Health Information*.

2015;34(1):1-8.

Buprenorphine Prescribing Resources

About Buprenorphine



- Buprenorphine is a partial opioid agonist approved for treatment of opioid use disorder.
- Buprenorphine is effective: it reduces drug use and death from opioids, keeps patients in treatment, and improves various health and social outcomes.
- Buprenorphine can be prescribed in office-based primary care settings, just like other medications prescribed for chronic health conditions.
- Any physician, nurse practitioner (NP), or physician assistant (PA) can prescribe buprenorphine after obtaining a waiver.

Email

buprenorphine@health.nyc.gov
for additional information



Prescribing Resources

The NYC Department of Health and Mental Hygiene (DOHMH) provides free resources for NYC health care providers to prescribe buprenorphine, including buprenorphine waiver training, clinical mentorship, technical assistance, and educational materials:

Training

- Follows “half-and-half” format: 4 hours of live instruction and 4 hours of online self-study
- Fulfills training requirement for physicians to apply for federal authorization to prescribe buprenorphine (also known as a “waiver”); NPs and PAs must complete an additional 16 hours of on-line training, for a total of 24 hours
- Offered approximately monthly
- Option to hold a training at your institution for groups of at least 20 prescribers

Mentorship

- Provides clinical mentorship for new or inexperienced prescribers
- Matches mentees with experienced buprenorphine prescribers (mentors); mentees from the same organization are matched with the same mentor
- Available to any NYC physician, NP, or PA who is newly waived to prescribe buprenorphine, or was previously waived but never or rarely prescribed
- Occurs via in-person meetings, telephone, email, video conference, and observing a mentor during a clinical session

Technical Assistance

- Supports implementation of buprenorphine prescribing into primary care settings of any size (e.g., hospital systems, solo practitioners, community-based settings, etc.)
 - Assists with determining a program model compatible with existing resources and interests
 - Includes guidance on logistics, workflow, staffing, training, policies, outreach, and legal requirements

Materials

- [Educational pamphlets and posters for patients, available in multiple languages](#)
- [Educational materials for providers](#)